What is she best known for?
The fields of study she is best known for:
Elizabeth A. Musgrove focuses on Cancer research, Cyclin D1, Cyclin D, Cyclin A and Cyclin A2.
Her Cancer research study combines topics in areas such as Carcinogenesis, Cancer, Metastasis and Cell growth.
Her Cancer research incorporates elements of PTEN and Pathology.
Her studies deal with areas such as Antiestrogen, Cortactin and Cyclin as well as Cyclin D1.
Her work investigates the relationship between Cyclin D and topics such as Cyclin B that intersect with problems in Molecular biology.
Her research in Cyclin A tackles topics such as Cell biology which are related to areas like Cyclin-dependent kinase 2.
Her most cited work include:
- Genomic analyses identify molecular subtypes of pancreatic cancer (1396 citations)
- Whole genomes redefine the mutational landscape of pancreatic cancer. (1318 citations)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (1304 citations)
What are the main themes of her work throughout her whole career to date?
Elizabeth A. Musgrove spends much of her time researching Cancer research, Internal medicine, Breast cancer, Cell cycle and Cyclin D1.
Elizabeth A. Musgrove combines subjects such as Cancer, Cyclin-dependent kinase, Estrogen receptor, Estrogen and Cyclin with her study of Cancer research.
Her study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology, Signal transduction and Oncology.
Her Breast cancer research includes elements of Endocrine system, Surgical oncology and Pathology.
Her research integrates issues of Retinoblastoma protein and Gene expression in her study of Cyclin D1.
The study incorporates disciplines such as Cyclin E and Cyclin A in addition to Cyclin D.
She most often published in these fields:
- Cancer research (77.00%)
- Internal medicine (46.95%)
- Breast cancer (45.07%)
What were the highlights of her more recent work (between 2011-2020)?
- Cancer research (77.00%)
- Pancreatic cancer (19.72%)
- Internal medicine (46.95%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Cancer research, Pancreatic cancer, Internal medicine, Cancer and Tamoxifen.
She interconnects Gene knockdown, DNA methylation, Mutation, Cancer cell and Signal transduction in the investigation of issues within Cancer research.
Her studies in Pancreatic cancer integrate themes in fields like Surgery, Transcriptome, KRAS, CDKN2A and DNA repair.
Her Internal medicine research is multidisciplinary, relying on both Oncology and Pathology.
She specializes in Cancer, namely Cell cycle.
Tamoxifen is the subject of her research, which falls under Breast cancer.
Between 2011 and 2020, her most popular works were:
- Genomic analyses identify molecular subtypes of pancreatic cancer (1396 citations)
- Whole genomes redefine the mutational landscape of pancreatic cancer. (1318 citations)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (1304 citations)
In her most recent research, the most cited papers focused on:
Elizabeth A. Musgrove mainly focuses on Pancreatic cancer, Cancer research, Cancer, Mutation and DNA repair.
Her Pancreatic cancer research incorporates elements of Surgery, KRAS, Clinical trial and CDKN2A.
Her KRAS research is multidisciplinary, incorporating perspectives in Exome sequencing, Copy number analysis, Wnt signaling pathway, Carcinogenesis and Molecular biology.
Her work carried out in the field of Cancer research brings together such families of science as Cyclin-dependent kinase, Cyclin A2, Cyclin E2, Cyclin E and Cell biology.
Her Cell biology study integrates concerns from other disciplines, such as Cyclin B, Cyclin E1, Cyclin D, Cyclin and Cyclin-dependent kinase 4.
Her work on MSH2, DNA mismatch repair and MLH1 is typically connected to Somatic hypermutation as part of general DNA repair study, connecting several disciplines of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
